These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 16953377

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Intracrystalline proteins and urolithiasis: a comparison of the protein content and ultrastructure of urinary calcium oxalate monohydrate and dihydrate crystals.
    Ryall RL, Chauvet MC, Grover PK.
    BJU Int; 2005 Sep; 96(4):654-63. PubMed ID: 16104927
    [Abstract] [Full Text] [Related]

  • 47. [Clinical studies of the recurrence of urolithiasis (4). Crystal formation in urine and stone recurrence].
    Murayama T, Taguchi H.
    Hinyokika Kiyo; 1988 Sep; 34(9):1543-7. PubMed ID: 3213790
    [Abstract] [Full Text] [Related]

  • 48. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II.
    Milliner DS, Wilson DM, Smith LH.
    Kidney Int; 2001 Jan; 59(1):31-6. PubMed ID: 11135054
    [Abstract] [Full Text] [Related]

  • 49. Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis.
    Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A.
    Urol Int; 2004 Jan; 72 Suppl 1():6-10. PubMed ID: 15133325
    [Abstract] [Full Text] [Related]

  • 50. Physicochemical considerations in the development and prevention of calcium oxalate urolithiasis.
    Kok DJ, Papapoulos SE.
    Bone Miner; 1993 Jan; 20(1):1-15. PubMed ID: 8453319
    [Abstract] [Full Text] [Related]

  • 51. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
    Costa-Bauzá A, Perelló J, Isern B, Sanchis P, Grases F.
    BMC Urol; 2006 Jul 05; 6():16. PubMed ID: 16822299
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. A new approach to calculate the risk of calcium oxalate crystallization from unprepared native urine.
    Laube N, Schneider A, Hesse A.
    Urol Res; 2000 Aug 05; 28(4):274-80. PubMed ID: 11011968
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. [Effect of urine alkalization on excretion of renal citrate and degree of urine saturation with calcium oxalate in patients with calcium-oxalate urolithiasis and in healthy subjects].
    Boruczkowska A.
    Pol Arch Med Wewn; 1994 Feb 05; 91(2):77-83. PubMed ID: 8008619
    [Abstract] [Full Text] [Related]

  • 57. Effects of etidronate disodium on crystallizations in synthetic urine and calcium oxalate crystal adhesion to Madin-Darby canine kidney (MDCK) cells.
    Ebisuno S, Kohjimoto Y, Nishikawa T, Nishihata M, Inagaki T, Komura T, Ohkawa T.
    Int J Urol; 1998 Nov 05; 5(6):582-7. PubMed ID: 9855128
    [Abstract] [Full Text] [Related]

  • 58. The in-vivo effect of sodium-potassium citrate on the crystal growth rate of calcium oxalate and other parameters in human urine.
    Achilles W, Schulze D, Schalk C, Rodeck G.
    Urol Res; 1990 Nov 05; 18(1):1-6. PubMed ID: 2316065
    [Abstract] [Full Text] [Related]

  • 59. Molecular modifiers reveal a mechanism of pathological crystal growth inhibition.
    Chung J, Granja I, Taylor MG, Mpourmpakis G, Asplin JR, Rimer JD.
    Nature; 2016 Aug 25; 536(7617):446-50. PubMed ID: 27501150
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.